Skip to main content

Table 1 Patient characteristics: Immunohistochemical staining for oestrogen receptors (ER) (ER alpha, ER beta) and progesterone receptors (PR) (PR-A and PR-B) were performed and analysed as previously published by our research group[25]

From: Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer

Grade (%) 1 147 (51.2)
(n = 287) 2 93 (32.4)
  3 47 (16.4)
FIGO stage (%) I 219 (75.0)
(n = 292) II 21 (7.2)
  III 44 (15.1)
  IV 8 (2.7)
Histology (%) Endometrioid 212 (72.6)
(n = 292) Serous 23 (7.9)
  Clear cell 5 (1.7)
  Mucinous 12 (4.1)
  Squamous cell 1 (0.3)
  Mixed 34 (11.6)
  Undifferentiated 5 (1.7)
Patient age ± sem [y] (range)   65.1 ± 0.6 (35.6-88.1)
Deaths (%)   160 (54.8)
Survival ± sem [y] (95% CI)   13.6 ± 0.5 (12.6-14.6)
Follow up ± sem [y] (95% CI)   13.8 ± 0.3 (13.1-14.5)
Glycodelin (%) (n = 291) Low 79 (27.1)
  Intermediate 152 (52.2)
  High 60 (20.6)
Glycodelin A (%) (n = 289) Low 82 (28.4)
  Intermediate 181 (62.6)
  High 26 (9.0)
ER alpha (%) (n = 292) Positive 133 (45.5)
ER beta (%) (n = 292) Positive 40 (13.7)
PRA (%) (n = 292) Positive 121 (41.4)
PRB (%) (n = 292) Positive 134 (45.9)
Co-morbidities Hypertension (%) 116 (39.7)
  Diabetes (%) 33 (11.3)
  Obesity (%) 89 (30.5)
Lymphangiosis (%) (n = 292) Positive 27 (9.2)
  Negative 263 (90.1)
  Unknown 2 (0.7)
Hemangiosis (%) (n = 292) Positive 8 (2.7)
  Negative 281 (96.2)
  Unknown 3 (1.0)
Radiotherapy (%) (n = 292) Yes 116 (39.7)
  No 170 (58.2)
  Declined 6 (2.1)
Chemotherapy (%) (n = 292) Yes 7 (2.4)
  No 283 (96.9)
  Declined 2 (0.7)